On April 27, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib’s single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The webinar will take place on Thursday, April 30th, 2026, at 11:00 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar will feature KOL Mrinal Patnaik, MBBS, a physician scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota. He is the Chair of the Acute Leukemia and Myeloid Neoplasms group at Mayo Clinic, Rochester and is also the Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program. His main clinical and research interests lie in precision genomics and epigenetics and the application of the same to myeloid neoplasms and bone marrow failure syndromes. He directs the Mayo Clinic Clonal hematopoiesis Clinic (CHIP), bone marrow failure syndrome clinic and the short telomere clinic.
KOL Webinar Information
Interested parties can register for and access the live webcast by visiting the "Events" section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the discussion.
(Press release, Cardiff Oncology, APR 27, 2026, View Source [SID1234664830])